摘要
目的探讨贝达喹啉治疗耐多药结核病(MDR-TB)的效果及安全性。方法选取2018年6月至2021年6月江西省胸科医院收治的65例MDR-TB患者作为研究对象,通过随机数字表法将其分为观察组(n=33)和对照组(n=32)。对照组予以常规抗结核治疗,观察组在其基础上予以贝达喹啉治疗。连续治疗24周后,比较两组的疗效、症状恢复情况、治疗前后的免疫功能、治疗期间两组用药安全性。结果观察组患者的治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的痰培养转阴率及病灶空洞闭合率均高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的血清γ干扰素(IFN-γ)、免疫球蛋白(Ig)A、IgM以及IgG水平高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗期间QT间期延长发生率高于对照组,差异有统计学意义(P<0.05)。结论贝达喹啉治疗MDR-TB可有效提升临床治疗效果,加快患者痰培养转阴,促进病灶吸收,同时提高机体免疫水平,但用药时需注意密切观察患者心功能变化。
Objective To explore the effect and safety of Bedaquiline in the treatment of multidrug-resistant tuberculosis(MDR-TB).Methods Sixty-five patients with MDR-TB admitted to Jiangxi Chest Hospital from June 2018 to June 2021 were selected as the study objects,and were divided into observation group(n=33)and control group(n=32)by random number table method.The control group was treated with conventional antituberculosis therapy,and the observation group was treated with Bedaquinoline on the basis of it.After 24 weeks of continuous treatment,the efficacy,symptom recovery,immune function before and after treatment and drug safety during treatment were compared between the two groups.Results The total effective rate of observation group was higher than control group,the difference was statistically significant(P<0.05).The sputum culture negative conversion rate and cavity closure rate in observation group were higher than those in control group after treatment,and the differences were statistically significant(P<0.05).The levels of serum interferon-γ(IFN-γ),immunoglobulin(Ig)A,IgM and IgG in observation group were higher than those in control group after treatment,and the differences were statistically significant(P<0.05).The incidence of prolonged QT interval in observation group was higher than that in control group during treatment,and the difference was statistically significant(P<0.05).Conclusion Bedaquiline can effectively improve clinical curative effect on MDR-TB patients,accelerate negative conversion of sputum culture,promote lesions absorption and enhance immunity.However,it is necessary to pay close attentions to the changes of cardiac function during medication.
作者
李静虹
吴于青
LI Jinghong;WU Yuqing(The Sixth Department of Internal Medicine,Jiangxi Chest Hospital,Jiangxi Province,Nanchang330008,China)
出处
《中国当代医药》
CAS
2023年第7期73-76,共4页
China Modern Medicine
基金
江西省应用研究培育计划项目(20212BAG70015)。
关键词
贝达喹啉
耐多药结核病
疗效
安全性
Bedaquiline
Multidrug-resistant tuberculosis
Curative effect
Safety
